Background: Cystic fibrosis (CF) patients present an increased risk of osteoporosis, and increased fracture rate. Several factors have been identified as modulators of bone metabolism and bone mineral density (BMD). Aims: To evaluate BMD and serum markers of bone turnover and establish their relationships with serum concentrations of interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α, IGF-I, IGF-II, IGF binding protein (IGFBP)-2, IGFBP-3, and parathyroid hormone (PTH) in young adult CF patients. Methods: Seventeen young adult CF patients (4 M, 13 F; mean age: 26.6 ± 1.1 years) were enrolled in the study and analysed as a whole and as two subgroups according to the Shwachman-Kulczycki score. BMD was assessed at the lumbar spine (L1–L4) by dual energy X-ray absorptiometry (DXA Hologic QDR 2000). Bone turnover was assessed by measuring serum levels of osteocalcin (OC) and serum carboxyterminal propeptide of type I collagen (PICP) as markers of bone formation, and serum cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as a marker of bone resorption. Serum IGFs, IGFBPs, and cytokines were assayed using special commercial kits. Daily calcium intake and weekly physical activity were estimated by questionnaires. Forced expiratory volume in one second was used to assess pulmonary function. Results: Lumbar BMD was normal, although there was a tendency to be lower in the patients with a lower clinical score. Both OC and PICP were increased, whereas ICTP was normal. Lumbar BMD was positively correlated with pulmonary function. IL-6 and C-reactive protein (markers of inflammation) were inversely correlated with PICP. Serum ICTP levels were correlated with serum IGF-I levels.No significant relationship was detected among lumbar BMD, markers of bone turnover and PTH, IGF-I, IGF-II, IGFBP-2, IGFBP-3, TNF-α, IL-1β, and body mass index Z-score. Conclusions: Bone turnover is abnormal in CF patients. Young adult CF patients with satisfying clinical status and nutritional conditions have normal BMD and increased serum OC and PICP levels.

Keywords:
Bone mineral density, Cystic fibrosis, IGF-I, Interleukin-6, Osteocalcin
1.
Haworth CS, Selby PL, Webb AK, Dodd ME, Musson H, McL Niven R, Economou G, Horrocks AW, Freemont AJ, Mawer EB, Adams JE: Low bone mineral density in adults with cystic fibrosis. Thorax 1999;54:961–967.
2.
Conway SP, Morton AM, Oldroyd B, Truscott JG, White H, Smith AH, Haigh I: Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax 2000;55:798–804.
3.
Sood M, Hambleton G, Super M, Fraser WD, Adams JE, Mughal MZ. Bone status in cystic fibrosis. Arch Dis Child 2001;84:516–520.
4.
Hardin DS, Arumugam R, Seilheimer DK, LeBlanc A, Ellis KJ: Normal bone mineral density in cystic fibrosis. Arch Dis Child 2001;84:363–368.
5.
Buntain HM, Greer RM, Schluter PJ, Wong JCH, Batch JA, Potter JM, Lewindon PJ, Powell E, Wainwright CE, Bell SC: Bone mineral density in Australian children, adolescents and adults with cystic fibrosis: a controlled cross sectional study. Thorax 2000;59:149–155.
6.
Baroncelli GI, De Luca F, Magazzù G, Arrigo T, Sferlazzas C, Carmelo C, Bertelloni S, Saggese G: Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res 1997;41:397–403.
7.
Girasole G, Giuliani N: The physiopathology of osteoporosis. Ann Ital Med Int 1995;10:9–17.
8.
Hanevold CD, Yamaguchi DT, Jordan SC: Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells. J Bone Miner Res 1993;8:1191–2000.
9.
Thore M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Saaf M, Baylink DJ, Mohan S: Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and –5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy. J Bone Miner Res 1998;13:891–899.
10.
Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu J-L, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D: Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 2002;110:771–781.
11.
Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ: Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764–1769.
12.
Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc 2002;23:19–25.
13.
Taylor AM, Bush A, Thomson A, Oades PJ, Marchant JL, Bruce-Morgan C, Holly J, Ahmed L, Dunger DB: Relation between insulin-like growth factor-I, body mass index, and clinical status in cystic fibrosis. Arch Dis Child 1997;76:304–309.
14.
Street ME, Volta C, Spaggiari C, Ziveri MA, Grzincich GL, Bernasconi S: Inflammation is a modulator of the insulin-like growth factor (IGF)/IGF-binding protein system inducing reduced bioactivity of IGFs in cystic fibrosis. Eur J Endocrinol 2006;154:47–52.
15.
Khosla S, Hassoun AAK, Baker BK, Liu F, Zein N, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL, Conover CA: Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis: potential insights into increasing bone mass in adults. J Clin Invest 1998;101:2165–2173.
16.
Marshall WA, Tanner J: Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303.
17.
Marshall WA, Tanner J: Variations in pattern of pubertal changes in boys. Arch Dis Child 1969;45:13–23.
18.
Food and Nutrition Board: National Research Council Recommended Dietary Allowances, ed 10. National Academy Press, Washington, DC, 1989, pp 174–184.
19.
Italian Society for Human Nutrition. Recommended Dietary Allowances (LARN) Revision. Litotipografia Zesi, Rome, 1996.
20.
Hansen CR, Pressler T, Koch C, Hoiby N: Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibrosis 2005;4:35–40.
21.
Shwachman H, Kulczycki LL: Long-term study of 105 patients with cystic fibrosis. Am J Dis Child 1958;96:6–15.
22.
Cacciari E, Milani S, Balsamo A, Dammacco F, De Luca F, Chiarelli F, Pasquino AM, Tonini G, Vanelli M: Italian cross-sectional growth charts for height, weight and BMI (6–20 years). Eur J Clin Nutr 2002;56:171–180.
23.
Polgar G, Promadhat V: Pulmonary Function Testing in Children: Techniques and Standards. WB Saunders, Philadelphia, 1971.
24.
Slemenda CW, Miller JZ, Hui SL, Reister TK, Johnston CC: Role of physical activity in the development of skeletal mass in children. J Bone Miner Res 1991;6:1227–1233.
25.
Fuhlbrigge AL, Bae SJ, Weiss ST, Kuntz KM, Paltiel AD: Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol 2006;117:359–366.
26.
Halpern MT, Schmier JK, Van Kerkhove MD, Watkins M, Karlberg CJ: Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Ann Allergy Asthma Immunol 2004;92:201–207.
27.
Van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–787.
28.
Blake GM, Fogelman I: Bone densitometry, steroids and osteoporosis. Curr Opin Nephrol Hypertens 2002;11:641–647.
29.
Street ME, Camacho-Hubner C, de’Angelis GL, Ziveri M, Giovannelli G, Bernasconi S, Savage MO. The insulin-like (IGF)-IGF binding protein (IGFBP) system is modulated by interleukin-1β and interleukin-6 in chronic inflammatory bowel disease. Horm Res 2004;61:159–164.
30.
King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, Ebeling PR, Wilson JW: Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur Respir J 2005;25:54–61.
31.
Ionescu AA, Nixon LS, Evans WD, Stone MD, Lewis-Jenkins V, Chatham K, Shale DJ: Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med 2000;162:789–794.
32.
Haworth CS, Selby PL, Webb AK, Martin L, Elborn JS, Sharples LD, Adams JE: Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004;59:613–617.
33.
Greer RM, Buntain HM, Potter JM, Wainwright CE, Wong JC, O’Rourke PK, Francis PW, Bell SC, Batch JA.: Abnormalities of the PTH-vitamin D axis and bone turnover markers in children, adolescents and adults with cystic fibrosis: comparison with healthy controls. Osteoporos Int 2003;14:404–411.
34.
Conway SP: Impact of lung inflammation on bone metabolism in adolescents with cystic fibrosis. Peadiatr Respir Rev 2001;2:324–331.
35.
Buntain HM, Schluter PJ, Bell SC, Greer RM, Wong JC, Batch J, Lewindon P, Wainwright CE: Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis. Thorax 2006;61:146–154.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.